Biotechnology

Session EX2
Executive Series

Session Description

Biotechnology is the fastest growing sector of the drug industry; each year biotech makes up a larger percentage of the total number of pharmaceutical products. The industry’s R&D pipeline currently contains approximately 12,000 molecules across 150 different disease areas. There continues to be significant innovation and technological advancement which is changing the development and manufacturing landscape. This program will address several key technological areas that are a priority to realize the potential of biotechnology.

Leaders

Speakers

Jeff Campie, USA
Richard Forsyth, Senior Consultant, Hyde Engineering + Consulting, USA
Nigel Hamilton, Global Quality, Strategy and Process Excellence, Sanofi Aventis, United Kingdom
Aisling Horan, Validation Scientist, Alkermes Plc, Ireland
Edwin Melendez, Principle Consultant, Parexel, USA
Mark O'Reilly, Director Engineering, Alkermes Pharma Ireland Ltd, Ireland
Kimberly Ray, A. Director Project Mgmt, Oso Biopharmaceuticals Mfg LLC, USA
Julian Wilkins, Vice President, PharmaConsult US Inc, USA
Paul Wreglesworth, Independent Consultant, United Kingdom

Presentation Titles

The Business of Biotech & Innovation Immunotherapies and Tissue Culture Manufacturing Technologies